C-OCOTAKL Therapeutics
plant-derived metabolites, NF-kB/Nrf2 modulation, senotherapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OCOT
C-OCOTC-OCOTplant-derived metabolites, NF-kB/Nrf2 modulation, senotherapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
AKL Therapeutics presents itself as a company focused on radically improving healthspan by developing a novel multifactorial therapeutic approach to osteoarthritis, and more broadly by creating therapies for inflammatory diseases with high unmet need.
SourceAKL Therapeutics presents the belief that healthspan can be radically improved by developing a novel multifactorial drug approach to osteoarthritis, framing osteoarthritis as a major ageing-related condition that also affects many people before age 65 and positioning its work as relevant to other diseases of ageing.
SourceAKL Therapeutics presents its position as radically improving healthspan through a novel multifactorial approach to osteoarthritis, while also developing a novel therapeutic for inflammatory diseases with high unmet need. The company frames osteoarthritis as an age-related condition affecting many people under 65 and suggests its APPA program shows promise in age-related diseases.
Source